Inventor
Margaret Karow
Inventor
Santa Rosa, CA, US
Overview
Patents· 55 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Kprimary
C07KPeptides30%
C12NMicroorganisms or enzymes17%
A01KAnimal husbandry13%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations13%
A61KPreparations for medical, dental or toiletry purposes13%
C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture10%
B60HArrangements of heating, cooling, ventilating or other air-treating devices specially adapted for passenger or goods spaces of vehicles3%
C07HSugars1%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests1%
PatentTitleYear
11,053,294Masked cytokine polypeptides202111,001,635Antitumor antagonists202110,905,108ADAM6 mice202110,905,109ADAM6 mice202110,851,157Antagonists targeting the TGF-b pathway202010,829,535Interleukin-2 muteins for the expansion of T-regulatory cells202010,694,725ADAM6 mice202010,640,800Mice that produce hybrid antibodies202010,597,453Antitumor immune checkpoint regulator antagonists202010,584,364Mice that produce hybrid antibodies202010,584,173Nucleic acids encoding high affinity antibodies to human IL-6 receptor202010,577,430ADAM6 mice202010,542,735Humanized non-human animals with restricted immunoglobulin heavy chain loci202010,526,630Genetically modified mice that produce hybrid antibodies202010,378,040Mice that produce hybrid antibodies201910,378,039Mouse embryonic stem cells comprising a hybrid heavy chain immunoglobulin locus201910,378,037Methods of making a nucleic acid encoding a human variable region201910,378,038Mice that produce hybrid antibodies201910,227,625Methods of modifying eukaryotic cells201910,130,081Humanized universal light chain mice201810,072,095ADAM6 mice20189,932,380Interleukin-2 muteins for the expansion of T-regulatory cells20189,884,916'High affinity antibodies to human IL-6 receptor'20189,708,635'Methods of making a nucleic acid encoding a human variable region'20179,580,486'Interleukin-2 muteins for the expansion of T-regulatory cells'20179,528,136'Methods of modifying eukaryotic cells'20169,388,446'Methods of producing hybrid antibodies'20169,382,567'Methods of producing hybrid antibodies'20169,376,699'Methods of producing hybrid antibodies'20169,371,553'Genetically modified mice that produce hybrid antibodies'20169,353,394'Methods of producing hybrid antibodies'20169,315,843'Methods of producing hybrid antibodies'20169,308,256'Method of treating rheumatoid arthritis with an anti-IL-6R antibody'20168,895,802'Genetically modified mice that produce hybrid antibodies'20148,895,801'Methods of producing hybrid antibodies'20148,791,323'Hybrid antibodies comprising human variable regions and mouse constant regions produced in a genetically modified mouse'20148,568,721'Method of treating rheumatoid arthritis with an anti-IL-6R antibody'20138,414,876'Methods of using IL-1 antagonists to treat autoinflammatory disease'20138,192,741'Method of treating rheumatoid arthritis with an anti-IL-6R antibody'20128,183,014'High affinity antibodies to human IL-6 receptor'20128,105,805'High affinity human antibodies to human IL-18 receptor'20128,080,248'Method of treating rheumatoid arthritis with an IL-6R antibody'20118,043,617'Human antibodies to human IL-6 receptor'20118,003,103'High affinity human antibodies to human IL-18 receptor'20117,732,167'Interferon-α/β binding fusion proteins and therapeutic uses thereof'20107,666,622'Monomeric self-associating fusion polypeptides and therapeutic uses thereof'20107,615,220'High affinity human antibodies to human IL-18 receptor'20097,608,430'Interferon-γ antagonists and therapeutic uses thereof'20097,582,298'High affinity antibodies to human IL-6 receptor'20097,557,084'IL-18 specific polypeptides and therapeutic uses thereof'20097,459,426'Methods of using IL-1 antagonists to treat autoinflammatory disease'20087,410,781'IL-4/IL-13 specific polypeptides and therapeutic uses thereof'20087,396,664'VEGF-binding fusion proteins and nucleic acids encoding the same'20087,361,350'Use of an IL-1 antagonist for treating arthritis'20087,083,950'High affinity fusion proteins and therapeutic and diagnostic methods for use'2006Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2006–2021Patents assigned to REGENERON PHARMA (45)· patent assignee history
2006–2010Based in Putnam Valley, NY, US· patent location history
2009–2012Based in Camarillo, CA, US· patent location history
2011–2018Patents assigned to KAROW MARGARET (9)· patent assignee history
2011–2018Patents assigned to STEVENS SEAN (8)· patent assignee history
2011–2013Patents assigned to FAIRHURST JEANETTE L (5)· patent assignee history
2011–2013Patents assigned to MARTIN JOEL H (5)· patent assignee history
2012–2021Based in Santa Rosa, CA, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| REGENERON PHARMA | 45 | 2006–2021 |
| KAROW MARGARETself | 9 | 2011–2018 |
| STEVENS SEAN | 8 | 2011–2018 |
| FAIRHURST JEANETTE L | 5 | 2011–2013 |
| MARTIN JOEL H | 5 | 2011–2013 |
Locations
| Location | Patents | Span |
|---|---|---|
| Santa Rosa, California, US | 40 | 2012–2021 |
| Putnam Valley, New York, US | 8 | 2006–2010 |
| Camarillo, California, US | 7 | 2009–2012 |